# Ireland Natalizumab (TYSABRI) Observational Program

> **NCT01943526** · — · COMPLETED · sponsor: **Biogen** · enrollment: 191 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** natalizumab

## Key facts

- **NCT ID:** NCT01943526
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-30
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2018-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01943526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01943526, "Ireland Natalizumab (TYSABRI) Observational Program". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01943526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*